Apellis Pharmaceuticals, Inc. (APLS) Financial Statements (2026 and earlier)

Company Profile

Business Address 100 FIFTH AVENUE
WALTHAM, MA 02451
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)
Annual | Quarterly

3/31/2026
MRQ
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments466,233411,290351,185551,801700,550877,648
Cash and cash equivalent466,233411,290351,185551,801640,192565,779
Short-term investments     60,358311,869
Restricted cash and investments1,5271,3221,1141,2731,5631,266
Receivables366,221264,926206,4427,72710,103 
Inventory, net of allowances, customer advances and progress billings142,55681,404146,36285,71416,286 
Inventory142,55681,404146,36285,71416,286 
Prepaid expense9,51518,36838,82036,35024,86811,400
Other current assets  11,64422,40836,65870,67726,878
Other undisclosed current assets28,788     
Total current assets:1,014,840788,954766,331719,523824,047917,192
Noncurrent Assets
Inventory, Noncurrent34,95975,713    
Operating lease, right-of-use asset18,19516,08316,74518,74719,90117,719
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization1,7082,9524,3456,1486,1776,803
Other noncurrent assets5,5551,3491,30915,79931,64018,855
Total noncurrent assets:60,41796,09722,39940,69457,71843,377
TOTAL ASSETS:1,075,257885,051788,730760,217881,765960,569
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities222,847178,756165,322132,481120,148120,412
Accounts payable56,79838,57237,51637,34216,9098,477
Accrued liabilities166,049140,184127,80695,139103,239111,935
Debt93,662     
Other undisclosed current liabilities7,0876,75382,27135,12911,6997,915
Total current liabilities:323,596185,509247,593167,610131,847128,327
Noncurrent Liabilities
Long-term debt and lease obligation361,664452,83093,03392,736206,105374,047
Long-term debt, excluding current maturities361,664452,83093,03392,736189,024358,830
Liabilities, other than long-term debt19,85018,17313,76614,352  
Other liabilities7,9037,9722,312   
Operating lease, liability11,94710,20111,45414,35217,08115,217
Other undisclosed noncurrent liabilities   239,817315,647328,070238,421
Total noncurrent liabilities:381,514471,003346,616422,735551,256627,685
Total liabilities:705,110656,512594,209590,345683,103756,012
Equity
Equity, attributable to parent370,147228,539194,521169,872198,662204,557
Common stock12121211108
Additional paid in capital3,385,2163,267,2013,035,5392,479,5961,857,4301,131,013
Accumulated other comprehensive loss(2,103)(3,308)(3,542)(875)(2,090)(117)
Accumulated deficit(3,012,978)(3,035,366)(2,837,488)(2,308,860)(1,656,688)(926,347)
Total equity:370,147228,539194,521169,872198,662204,557
TOTAL LIABILITIES AND EQUITY:1,075,257885,051788,730760,217881,765960,569

Income Statement (P&L) ($ in thousands)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenues1,003,782781,367396,59175,42266,563250,646
Cost of revenue
(Cost of Product and Service Sold)		(20,500)(19,000)(6,400)   
Gross profit:983,282762,367390,19175,42266,563250,646
Operating expenses(948,355)(946,346)(913,712)(670,035)(602,840)(464,372)
Other undisclosed operating income20,50019,0006,400   
Operating income (loss):55,427(164,979)(517,121)(594,613)(536,277)(213,726)
Nonoperating income13,01010,60320,2068,6261,7803,663
Investment income, nonoperating13,14312,77320,9338,9144184,164
Other nonoperating income (expense)(133)(2,170)(727)(288)1,362(501)
Interest and debt expense(44,327)(40,391)    
Other undisclosed loss from continuing operations before equity method investments, income taxes      (132,966)
Income (loss) from continuing operations before equity method investments, income taxes:24,110(194,767)(496,915)(585,987)(534,497)(343,029)
Other undisclosed loss from continuing operations before income taxes  (1,949)(29,581)(65,516)(211,505) 
Income (loss) from continuing operations before income taxes:24,110(196,716)(526,496)(651,503)(746,002)(343,029)
Income tax expense(1,722)(1,162)(2,132)(669)(352)(1,845)
Income (loss) from continuing operations:22,388(197,878)(528,628)(652,172)(746,354)(344,874)
Loss before gain (loss) on sale of properties:✕✕✕✕✕(746,354)(344,874)
Net income (loss) available to common stockholders, basic:22,388(197,878)(528,628)(652,172)(746,354)(344,874)
Interest on convertible debt3,607     
Net income (loss) available to common stockholders, diluted:25,995(197,878)(528,628)(652,172)(746,354)(344,874)

Comprehensive Income ($ in thousands)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Net income (loss):22,388(197,878)(528,628)(652,172)(746,354)(344,874)
Other comprehensive income      37
Comprehensive income (loss):22,388(197,878)(528,628)(652,172)(746,354)(344,837)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent1,205234(2,667)1,215(1,973) 
Comprehensive income (loss), net of tax, attributable to parent:23,593(197,644)(531,295)(650,957)(748,327)(344,837)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: